D
David Cohen
Researcher at Pierre-and-Marie-Curie University
Publications - 787
Citations - 45536
David Cohen is an academic researcher from Pierre-and-Marie-Curie University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 83, co-authored 635 publications receiving 37722 citations. Previous affiliations of David Cohen include University of California, Berkeley & University of Michigan.
Papers
More filters
Journal ArticleDOI
Intensive mental health treatment for neglecting and/or abusive parents: Outcome and impact on the quality of early parents child interactions
S. Viaux-Savelon,S. Vatageot,Laurence Camon-Sénéchal,L.P. Derotus,Élisabeth Aidane,Didier Rabain,Miri Keren,David Cohen +7 more
Book
Phil Ochs: A Bio-Bibliography
TL;DR: Ochs as mentioned in this paper is a collection of essays written by Ochs about his life and work, including: Biography Writings by Ochess Writings about Ochesmans and Ochesman.
Journal ArticleDOI
Effect of intensive versus limited monitoring on clinical trial conduct and outcomes: A randomized trial.
TL;DR: In this article, the authors conducted a patient-level block-randomized controlled trial evaluating the effect of intensive versus limited monitoring on cardiovascular clinical trial conduct and outcomes nested within the CoreValve Continued Access and Expanded Use Studies.
DatasetDOI
Study of Instructional Improvement (SII)
TL;DR: In this paper, the authors conducted a large-scale, mixed method, longitudinal study of instructional improvement to investigate the design, implementation, and effects on student achievement of three of the most widely-adopted whole-school school reform programs in the United States: the Accelerated Schools (ASP), America's Choice (AC), and Success for All (SFA).
Mp01-06 office based transperineal laser ablation for benign prostatic hyperplasia: 3 & 6 months outcomes
Luna Eusebio,L. Avila,Alberto Lopez-Prieto,Edward L. Gheiler,Ariel Kaufman,David Cohen,Fernando J. Bianco +6 more
TL;DR: Three month outcomes showed subjective and objective sustained improvement in over 80% of patients for at least 6 months and this novel and promising approach demands further evaluation in phase II-III trials.